Korean J Psychopharmacol.
2008 Jul;19(4):187-196.
Efficacy and Safety of Long-term Aripiprazole Therapy in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder: A 52-week, Prospective, Open-label Study
- Affiliations
-
- 1Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea. kwonjs@plaza.snu.ac.kr
- 2Department of Psychiatry, Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- 3Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 4Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
- 5Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.
- 6Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- 7Department of Psychiatry, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.
- 8Department of Psychiatry, Chungnam National University College of Medicine, Daejeon, Korea.
- 9Department of Psychiatry, Seoul National Hospital, Seoul, Korea.
- 10Department of Psychiatry, Eulji University College of Medicine, Daejeon, Korea.
- 11Department of Psychiatry, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea.
Abstract
OBJECTIVE
We investigated the long-term efficacy, safety, and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder in Korea.
METHODS
This was an open-label, multi-center, single-arm, 52-week study of patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder. Korean patients (N=300) experiencing either a first episode or recurrence participated in this study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score. Secondary efficacy measures included the PANSS positive and negative subscales, and the Clinical Global Impression-Severity of Illness (CGI-S). Safety was evaluated prospectively by recording treatmentemergent adverse events; measuring extrapyramidal symptoms (EPS), vital signs, and body weight; and performing laboratory tests.
RESULTS
Overall, 55 (18.33%) of the patients completed the entire 52-week study. Treatment with aripiprazole provided rapid and significant improvement in all of the efficacy measures. Comparing PANSS total scores, PANSS positive subscale scores, and CGI-S scores, first-episode patients showed significant improvement than the patients who had experienced at least one recurrence. There were no significant differences in the mean change of EPS during the study, except for akathisia at week 8 and a significant decrease in serum prolactin level in patients experiencing first and recurrent episodes. At the end of the study, the mean weight gain was 2.40 kg.
CONCLUSION
Aripiprazole is effective and safe for patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder during a long-term, 52-week treatment. The result may be associated with the unique mechanism of aripiprazole. We have extended the findings of previous studies in the United States and other countries and demonstrated a similar effectiveness of aripiprazole for Korean patients.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of Long-term Aripiprazole Therapy in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder: A 52-week, Prospective, Open-label Study
- Efficacy and Safety of Aripiprazole during Acute Treatment Phase in Patients with Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder: An 8-Week, Prospective, Open-Label Study
- Effect of Long-Term Aripiprazole Therapy on Social Functioning in Korean Patients with Schizophrenia: A 52-Week, Prospective, Open-Label Study
- Schizoaffective Disorder
- Effects of Psychoeducation Program on Insight and Treatment Attitudes in Patients with Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder
